The decision to discontinue home isolation should be made in the context of local circumstances.
Assembled By :
Nilou Lab
Latest Update:
2022/06/28

The decision to discontinue home isolation should be made in the context of local circumstances.
Options now include both:
1) a time-since-illness-onset and time-since-recovery (non-test-based) strategy, and
2) a test-based strategy.
Time-since-illness-onset and time-since-recovery strategy (non-test-based strategy)*
Persons with COVID-19 who have symptoms and were directed to care for themselves at home may discontinue home isolation under the following conditions:
At least 3 days (72 hours) have passed since recovery defined as resolution of fever without the use of fever-reducing medications and improvement in respiratory symptoms (e.g., cough, shortness of breath); and,
At least 7 days have passed since symptoms first appeared.
Test-based strategy (simplified from initial protocol) Previous recommendations for a test-based strategy remain applicable;
however, a test-based strategy is contingent on the availability of ample testing supplies and laboratory capacity as well as convenient access to testing.
For jurisdictions that choose to use a test-based strategy, the recommended protocol has been simplified so that only one swab is needed at every sampling.
Persons who have COVID-19 who have symptoms and were directed to care for themselves at home may discontinue home isolation under the following conditions:
Resolution of fever without the use of fever-reducing medications and
Improvement in respiratory symptoms (e.g., cough, shortness of breath) and
Negative results of an FDA Emergency Use Authorized molecular assay for COVID-19 from at least two consecutive nasopharyngeal swab specimens collected ≥24 hours apart** (total of two negative specimens).
See Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons Under Investigation (PUIs) for 2019 Novel Coronavirus (2019-nCoV)for specimen collection guidance.
Individuals with laboratory-confirmed COVID-19 who have not had any symptoms may discontinue home isolation when at least 7 days have passed since the date of their first positive COVID-19 diagnostic test and have had no subsequent illness.
Footnote
* This recommendation will prevent most, but may not prevent all instances of secondary spread.
** The risk of transmission after recovery, is likely very substantially less than that during illness.
* All test results should be final before isolation is ended. Testing guidance is based upon limited information and is subject to change as more information becomes available.
References: https://www.cdc.gov/coronavirus/2019-ncov/hcp/disposition-in-home-patients.html
Options now include both:
1) a time-since-illness-onset and time-since-recovery (non-test-based) strategy, and
2) a test-based strategy.
Time-since-illness-onset and time-since-recovery strategy (non-test-based strategy)*
Persons with COVID-19 who have symptoms and were directed to care for themselves at home may discontinue home isolation under the following conditions:
At least 3 days (72 hours) have passed since recovery defined as resolution of fever without the use of fever-reducing medications and improvement in respiratory symptoms (e.g., cough, shortness of breath); and,
At least 7 days have passed since symptoms first appeared.
Test-based strategy (simplified from initial protocol) Previous recommendations for a test-based strategy remain applicable;
however, a test-based strategy is contingent on the availability of ample testing supplies and laboratory capacity as well as convenient access to testing.
For jurisdictions that choose to use a test-based strategy, the recommended protocol has been simplified so that only one swab is needed at every sampling.
Persons who have COVID-19 who have symptoms and were directed to care for themselves at home may discontinue home isolation under the following conditions:
Resolution of fever without the use of fever-reducing medications and
Improvement in respiratory symptoms (e.g., cough, shortness of breath) and
Negative results of an FDA Emergency Use Authorized molecular assay for COVID-19 from at least two consecutive nasopharyngeal swab specimens collected ≥24 hours apart** (total of two negative specimens).
See Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons Under Investigation (PUIs) for 2019 Novel Coronavirus (2019-nCoV)for specimen collection guidance.
Individuals with laboratory-confirmed COVID-19 who have not had any symptoms may discontinue home isolation when at least 7 days have passed since the date of their first positive COVID-19 diagnostic test and have had no subsequent illness.
Footnote
* This recommendation will prevent most, but may not prevent all instances of secondary spread.
** The risk of transmission after recovery, is likely very substantially less than that during illness.
* All test results should be final before isolation is ended. Testing guidance is based upon limited information and is subject to change as more information becomes available.
References: https://www.cdc.gov/coronavirus/2019-ncov/hcp/disposition-in-home-patients.html
Other Article
-
Launch of the first FDA-approved technology in Iran to diagnose HPV (updated)
-
Errors in POCT (Point of Collection Testing) and alternative site testing
-
First-Trimester Contingent Screening for Trisomy 21 by Fetal Nuchal Translucency and Maternal Serum Biomarkers and Maternal Blood Cell-Free DNA Testing
-
Human papilloma virus (HPV) genotypes concordance between Iranian couples referrals
-
Some Points about Serum biochemistry in prenatal screening
-
Some points about the Nuchal Translucency in Ultrasound according to FMF
-
Non-invasive prenatal test to screen common trisomies in twin pregnancies
-
New Findings on the Use of Fibrinogen in Gynecological Diseases
-
Fine-tuning of routine combined first- trimester screening
-
Coronavirus and Laboratory Quality